https://www.businesstoday.in/latest/corporate/story/emcure-cuts-prices-of-novos-semaglutide-brand-poviztra-by-up-to-55-523816-2026-04-02
Emcure cuts prices of Novo’s semaglutide brand Poviztra by up to 55% - BusinessToday
Apr 2, 2026 - Move follows patent expiry and intensifying competition, with monthly therapy costs now starting at Rs 3,999.
semaglutide brandup tocutspricesbusinesstoday